View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2017	May 02, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Document period end date	Mar. 31, 2017
Amendment flag	false
Document Period Focus	Q1
Document Fiscal Year Focus	2017
Current fiscal year end date	--12-31
Entity central index key	0001123494
Entity current reporting status	Yes
Entity filer category	Accelerated Filer
Entity registrant name	HARVARD BIOSCIENCE INC
Entity voluntary filers	No
Entity well known seasoned issuer	No
Entity common stock shares outstanding		34,618,897
Trading Symbol	HBIO

Statements of Financial Position - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Current Assets:
Cash and cash equivalents	$ 4,599	$ 5,596
Accounts receivable, net of allowance for doubtful accounts of $559 and $611, respectively	15,479	15,746
Inventories	20,282	19,955
Other receivables and other assets	4,761	4,175
Total current assets	45,121	45,472
Property, plant and equipment, net	4,268	4,296
Deferred income tax assets - non-current	1,179	1,157
Amortizable intangible assets, net	17,070	17,471
Goodwill	38,398	38,032
Other indefinite lived intangible assets	1,216	1,209
Other assets	144	128
Total Assets	107,396	107,765
Current liabilities:
Current portion, long-term debt	2,722	2,372
Accounts payable	5,835	6,196
Deferred revenue	598	500
Accrued income taxes payable	99	223
Accrued expenses	4,324	4,550
Other liabilities - current	478	760
Total current liabilities	14,056	14,601
Long-term debt	10,931	11,374
Deferred income tax liabilities - non-current	6,460	6,417
Other liabilities- non current	3,234	3,177
Total liabilities	34,681	35,569
Stockholders Equity Abstract
Preferred stock, par value $0.01 per share, 5,000,000 shares authorized	0	0
Common stock, par value $0.01 per share, 80,000,000 shares authorized; 42,364,404 and 42,186,827 shares issued and 34,618,897 and 34,441,320 shares outstanding, respectively	418	418
Additional paid-in-capital	215,842	215,134
Accumulated deficit	(117,168)	(116,030)
Accumulated other comprehensive loss	(15,709)	(16,658)
Treasury stock at cost, 7,745,507 common shares	(10,668)	(10,668)
Total stockholders' equity	72,715	72,196
Total liabilities and stockholders' equity	$ 107,396	$ 107,765

Statements of Financial Position (Parentheticals) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
CONSOLIDATED BALANCE SHEETS
Allowance for doubtful accounts	$ 559	$ 611
Preferred Stock Par value	$ 0.01	$ 0.01
Preferred Stock - Shares Authorized	5,000,000	5,000,000
Common stock par value	$ 0.01	$ 0.01
Common Stock- Shares Authorized	80,000,000	80,000,000
Common Stock- Shares Issued	42,364,404	42,186,827
Common Stock- Shares Outstanding	34,618,897	34,441,320
Treasury Stock common shares	7,745,507	7,745,507

Statements of Operations - USD ($) $ in Thousands	3 Months Ended
Statements of Operations - USD ($) $ in Thousands	Mar. 31, 2017	Mar. 31, 2016
CONSOLIDATED STATEMENTS OF OPERATIONS
Revenues	$ 24,156	$ 26,963
Cost of revenues (exclusive of items shown separately below)	12,657	14,018
Gross profit	11,499	12,945
Sales and marketing expenses	5,048	5,102
General and administrative expenses	5,206	5,948
Research and development expenses	1,285	1,425
Restructuring charges (credits)	0	11
Amortization of intangible assets	599	680
Total operating expenses, net	12,138	13,166
Operating (loss) income	(639)	(221)
Other income (expense):
Foreign exchange	(143)	(9)
Interest expense	(162)	(164)
Interest income	0	1
Other income (expense), net	(99)	(50)
Other expense, net	(404)	(222)
Loss before income taxes	(1,043)	(443)
Income tax expense	23	193
Net loss	$ (1,066)	$ (636)
Earnings (loss) per share:
Basic earnings per common share	$ (0.03)	$ (0.02)
Diluted Earnings Per Common Share	$ (0.03)	$ (0.02)
Weighted average common shares:
Basic	34,579,473	34,013,352
Diluted	34,579,473	34,013,352
Comprehensive loss:
Net loss	$ (1,066)	$ (636)
Foreign currency translation adjustments	942	616
Derivatives qualifying as hedges, net of tax:
Gain (loss) on derivative instruments designated and qualifying as cash flow hedges	4	(36)
Amounts reclassified from accumulated other comprehensive loss to net loss	3	13
Total Comprehensive Income (Loss), Net of Tax, total	$ (117)	$ (43)

Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
Statements of Cash Flows - USD ($) $ in Thousands	Mar. 31, 2017	Mar. 31, 2016
Cash flows from operating activities:
Net income (loss)	$ (1,066)	$ (636)
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation expense	863	754
Depreciation	306	385
Amortization Of Catalog Costs	9	3
Provision for allowance for doubtful accounts	(15)	37
Amortization of intangible assets	599	680
Amortization of deferred financing costs	19	28
Deferrred Income Taxes	0	4
Changes in operating assets and liabilities:
(Increase) decrease in accounts receivable	410	(463)
Increase in inventories	(300)	211
Increase in other receivables and other assets	(526)	(463)
Increase in trade accounts payable	(320)	(2,679)
(Decrease) increase in accrued income taxes	(110)	(77)
Increase in accrued expenses	(571)	1,481
(Decrease) increase in deferred revenue	92	32
Increase (decrease) in other liabilities	0	(23)
Net cash provided by operating activities	(610)	(726)
Cash flows (used in) provided by investing activities:
Additions to property, plant and equipment	(198)	(201)
Significant costs of product catalog design, development and production are capitalized and amortized over the expected useful life of the catalog.	(30)	(4)
Net cash used in investing activities	(228)	(205)
Cash flows provided by (used in) financing activities:
Repayments of debt	(1,113)	(2,613)
Net proceeds from issuance of debt	1,000	1,000
Net proceeds from issuance of common stock	(155)	(113)
Net cash (used in) provided by financing activities	(268)	(1,726)
Effect of exchange rate changes on cash	109	88
Increase in cash and cash equivalents	(997)	(2,569)
Cash and cash equivalents at the begining of period	5,596	6,744
Cash and cash equivalents at the end of period	4,599	4,175
Supplemental disclosures of cash flow information [Abstract]
Cash paid for interest	164	194
Cash paid for income taxes, net of refunds	$ 333	$ 171

Basis of Presentation and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2017
Basis of Presentation and Summary of Significant Accounting Policies Disclosure [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies Disclosure [Text Block]	HARVARD BIOSCIENCE, INC. NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS 1. Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation The unaudited consolidated financial statements of Harvard Bioscience, Inc. and its wholly-owned subsidiaries (collectively, “Harvard Bioscience” or the “Company”) as of March 31, 2017 and for the three months ended March 31, 2017 and 2016 have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. The December 31, 2016 consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016, which was filed with the SEC on March 17, 2017. In the opinion of management, all adjustments, which include normal recurring adjustments necessary to present a fair statement of financial position as of March 31, 2017, results of operations and comprehensive loss and cash flows for the three months ended March 31, 2017 and 2016, as applicable, have been made. The results of operations for the three months ended March 31, 2017 are not necessarily indicative of the operating results for the full fiscal year or any future periods. Summary of Significant Accounting Policies The accounting policies underlying the accompanying unaudited consolidated financial statements are those set forth in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016, which was filed with the SEC on March 17, 2017.

Recently Issued Accounting Pronouncements	3 Months Ended
Recently Issued Accounting Pronouncements	Mar. 31, 2017
Recently Issued Accounting Pronouncements [Abstract]
Recently Issued Accounting Pronouncements Disclosure [Text Block]	2. Recently Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, “Revenue from Contracts with Customers,” a new accounting standard that provides for a comprehensive model to use in the accounting for revenue arising from contracts with customers that will replace most existing revenue recognition guidance within generally accepted accounting principles in the United States. Under this standard, revenue will be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The Company expects to adopt this standard as of January 1, 2018 using the modified retrospective approach. The Company intends to complete a comprehensive assessment of its contracts in 2017 concerning any unique customer contract terms or transactions that could have implications to the timing of revenue recognition under the new guidance. The Company expects this undertaking will be complete in the second half of 2017. In February 2016, the FASB issued ASU 2016-02, Leases, which is intended to improve financial reporting about leasing transactions. The update requires a lessee to record on the balance sheet the assets and liabilities for the rights and obligations created by lease terms of more than 12 months. The update is effective for fiscal years beginning after December 15, 2018. The Company is evaluating the requirements of this guidance and has not yet determined the impact of the adoption on its consolidated financial position, results of operations and cash flows, however, assets and liabilities will increase upon adoption for right-of-use assets and lease liabilities. The Company’s future commitments under lease obligations are summarized in Note 10. Recently Adopted Accounting Pronouncements In March 2016, the FASB issued ASU 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which simplifies the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. The standard requires an entity to recognize all excess tax benefits and tax deficiencies as income tax benefit or expense in the income statement as discrete items in the reporting period in which they occur, and such tax benefits and tax deficiencies are not included in the estimate of an entity’s annual effective tax rate, applied on a prospective basis. Further, the standard eliminates the requirement to defer the recognition of excess tax benefits until the benefit is realized through a reduction to taxes payable. All excess tax benefits previously unrecognized, along with any valuation allowance, should be recognized on a modified retrospective basis as a cumulative adjustment to retained earnings as of the date of adoption. Under ASU 2016-09, an entity that applies the treasury stock method in calculating diluted earnings per share is required to exclude excess tax benefits and deficiencies from the calculation of assumed proceeds since such amounts are recognized in the income statement. Excess tax benefits should also be classified as operating activities in the same manner as other cash flows related to income taxes on the statement of cash flows, as such excess tax benefits no longer represent financing activities since they are recognized in the income statement, and should be applied prospectively or retrospectively to all periods presented. The Company adopted ASU 2016-09 as of January 1, 2017. The Company recorded a cumulative increase in retained earnings of $0.5 million at the beginning of the first quarter of 2017 with a corresponding increase in deferred tax assets related to the prior years’ unrecognized excess tax benefits. An equal amount of valuation allowance was also recorded against these deferred tax assets with a corresponding decrease to retained earnings resulting in a net impact of $0. In addition, tax deficiencies related to vested restricted stock units and canceled stock options during the first quarter of 2017 have been recognized in the current period’s income statement. ASU 2016-09 also allows an entity to elect as an accounting policy either to continue to estimate the total number of awards for which the requisite service period will not be rendered or to account for forfeitures for service based awards as they occur. An entity that elects to account for forfeitures as they occur should apply the accounting change on a modified retrospective basis as a cumulative effect adjustment to retained earnings as of the date of adoption. The Company elected as an accounting policy to account for forfeitures for service based awards as they occur, and as a result, the Company recorded a cumulative effect adjustment of $0.1 million to reduce retained earnings with a corresponding increase in additional paid in capital related to the prior years’ stock-based compensation expense as required under the modified retrospective approach. The tax effect of this adjustment, which included the impact of a valuation allowance was immaterial.

Accumulated Other Comprehensive Income

3 Months Ended

Mar. 31, 2017

Accumulated Other Comprehensive Income [Abstract]

Accumulated Other Comprehensive Income Disclosure [Text Block]

3. Accumulated Other Comprehensive Loss

Changes in each component of accumulated other comprehensive loss, net of tax are as follows:

		Foreign currency		Derivatives
		translation		qualifying as		Defined benefit
(in thousands)		adjustments		hedges		pension plans		Total

Balance at December 31, 2016	$	(14,200)	$	-	$	(2,458)	$	(16,658)

Other comprehensive income before reclassifications		942		4		-		946
Amounts reclassified from AOCI		-		3		-		3

Other comprehensive income		942		7		-		949

Balance at March 31, 2017	$	(13,258)	$	7	$	(2,458)	$	(15,709)

- Definition

The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e689-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=66004124&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e640-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e716-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e709-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e637-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e681-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Reclassification Adjustments
-URI http://asc.fasb.org/extlink&oid=6522872

+ Details

Goodwill and Other Intangible Assets

3 Months Ended

Mar. 31, 2017

Goodwill And Other Intangible Assets Disclosure [Abstract]

Goodwill And Other Intangible Assets Disclosure [Text Block]

4. Goodwill and Other Intangible Assets

Intangible assets consist of the following:

									Weighted
									Average
		March 31, 2017				December 31, 2016			Life	(a)
		(in thousands)
Amortizable intangible assets:		Gross		Accumulated Amortization		Gross		Accumulated Amortization
Existing technology	$	15,287	$	(12,020)	$	15,082	$	(11,710)	6.8	Years
Trade names		7,436		(3,617)		7,379		(3,479)	7.8	Years
Distribution agreements/customer relationships		23,136		(13,228)		22,976		(12,862)	8.7	Years
Patents		207		(131)		204		(119)	1.9	Years
Total amortizable intangible assets		46,066	$	(28,996)		45,641	$	(28,170)

Indefinite-lived intangible assets:
Goodwill		38,398				38,032
Other indefinite-lived intangible assets		1,216				1,209
Total goodwill and other indefinite-lived intangible assets		39,614				39,241

Total intangible assets, gross	$	85,680			$	84,882

(a) Weighted average life as of March 31, 2017.

The change in the carrying amount of goodwill for the three months ended March 31, 2017 is as follows:

			(in thousands)
Balance at December 31, 2016		$	38,032
	Effect of change in currency translation		366
Balance at March 31, 2017		$	38,398

Amortization of intangible assets

Intangible asset amortization expense was $0.6 million and $0.7 million for the three months ended March 31, 2017 and 2016, respectively. Amortization expense of existing amortizable intangible assets is currently estimated to be $2.4 million for the year ending December 31, 2017, $2.3 million for the year ending December 31, 2018, $2.1 million for the year ending December 31, 2019, $2.1 million for the year ending December 31, 2020 and $2.1 million for the year ending December 31, 2021.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Inventories

3 Months Ended

Mar. 31, 2017

Inventories Disclosure [Abstract]

Inventories Disclosure [Text Block]

5. Inventories

Inventories consist of the following:

			March 31,		December 31,
			2017		2016
			(in thousands)
Finished goods		$	9,686	$	9,340
Work in process			900		823
Raw materials			9,696		9,792
	Total	$	20,282	$	19,955

Property, Plant and Equipment

3 Months Ended

Mar. 31, 2017

Property, Plant and Equipment Disclosure [Abstract]

Property, Plant and Equipment Disclosure [Text Block]

6. Property, Plant and Equipment

As of March 31, 2017 and December 31, 2016, property, plant and equipment consist of the following:

		March 31,		December 31,
		2017		2016
		(in thousands)
Land, buildings and leasehold improvements	$	2,117	$	2,095
Machinery and equipment		7,395		7,224
Computer equipment and software		8,345		8,115
Furniture and fixtures		1,284		1,274
Automobiles		201		196
		19,342		18,904
Less: accumulated depreciation		(15,074)		(14,608)
Property, plant and equipment, net	$	4,268	$	4,296

Long Term Debt

3 Months Ended

Mar. 31, 2017

Long Term Debt Disclosure [Abstract]

Long Term Debt Disclosure [Text Block]

12. Long Term Debt

On August 7, 2009, the Company entered into an Amended and Restated Revolving Credit Loan Agreement related to a $20.0 million revolving credit facility with Bank of America, as agent, and Bank of America and Brown Brothers Harriman & Co as lenders (as amended, the “2009 Credit Agreement”). On March 29, 2013, the Company entered into a Second Amended and Restated Revolving Credit Agreement (as amended, the “2013 Credit Agreement”) with Bank of America, as agent, and Bank of America and Brown Brothers Harriman & Co, as lenders that amended and restated the 2009 Credit Agreement. Between September 2011 and March 2016, the Company entered into a series of amendments that among other things did the following:



on September 30, 2011, reduced interest rates to the London Interbank Offered Rate plus 3.0%;



on March 29, 2013, converted existing loan advances into a term loan in the principal amount of $15.0 million (the “2013 Term Loan”), provided a revolving credit facility in the maximum principal amount of $25.0 million (the “2013 Revolving Line”) and a delayed draw term loan (the “2013 DDTL”) of up to $15.0 million (all with a maturity date of March 29, 2018);



on October 31, 2013, reduced the 2013 DDTL from up to $15.0 million to up to $10.0 million;



on April 24, 2015, extended the maturity date of the 2013 Revolving Line to March 29, 2018 and reduced the interest rates on the 2013 Revolving Line, 2013 Term Loan and 2013 DDTL;



on June 30, 2015, amended our quarterly minimum fixed charge coverage financial covenant; and



on March 9, 2016, amended the principal payment amortization of the 2013 Term Loan and 2013 DDTL to five years, as well as amended our quarterly minimum fixed charge coverage financial covenant.

The maximum amount available under the 2013 Credit Agreement is $50.0 million as borrowings against the 2013 DDTL in excess of $10.0 million results in a dollar for dollar reduction in the 2013 Revolving Line capacity. The 2013 Revolving Line, 2013 Term Loan and 2013 DDTL each have a maturity date of March 29, 2018. Borrowings under the 2013 Term Loan and the 2013 DDTL accrue interest at a rate based on either the effective London Interbank Offered Rate (LIBOR) for certain interest periods selected by the Company, or a daily floating rate based on the British Bankers’ Association (BBA) LIBOR as published by Reuters (or other commercially available source providing quotations of BBA LIBOR), plus in either case, a margin of 2.75%. Additionally, the 2013 Revolving Line accrues interest at a rate based on either the effective LIBOR for certain interest periods selected by the Company, or a daily floating rate based on the BBA LIBOR, plus in either case, a margin of 2.25%. The Company was required to fix the rate of interest on at least 50% of the 2013 Term Loan and the 2013 DDTL through the purchase of interest rate swaps.

The loans evidenced by the 2013 Credit Agreement, or the 2013 Loans, are guaranteed by all of the Company’s direct and indirect domestic subsidiaries, and secured by substantially all of the assets of the Company and the guarantors. The 2013 Loans are subject to restrictive covenants under the 2013 Credit Agreement, and financial covenants that require the Company and its subsidiaries to maintain certain financial ratios on a consolidated basis, including a maximum leverage, minimum fixed charge coverage and minimum working capital. Prepayment of the 2013 Loans is allowed by the 2013 Credit Agreement at any time during the terms of the 2013 Loans. The 2013 Loans also contain limitations on the Company’s ability to incur additional indebtedness and requires lender approval for acquisitions funded with cash, promissory notes and/or other consideration in excess of $6.0 million and for acquisitions funded solely with equity in excess of $10.0 million.

As of March 31, 2017 and December 31, 2016, the Company had net borrowings of $13.7 million, respectively, outstanding under its 2013 Credit Agreement. The carrying value of the debt approximates fair value because the interest rate under the obligation approximates market rates of interest available to the Company for similar instruments. As of March 31, 2017, the Company was in compliance with all financial covenants contained in the 2013 Credit Agreement, was subject to covenant and working capital borrowing restrictions and had available borrowing capacity under its 2013 Credit Agreement of $5.2 million.

As of March 31, 2017, the weighted effective interest rates, net of the impact of the Company’s interest rate swaps, on its 2013 Term Loan, 2013 DDTL and 2013 Revolving Line borrowings were 3.96%, 3.83% and 3.23%, respectively.

As of March 31, 2017 and December 31, 2016, the Company’s borrowings were comprised of:

		March 31,		December 31,
		2017		2016
		(in thousands)
Long-term debt:
Term loan	$	5,062	$	5,400
DDTL		4,125		4,400
Revolving line		4,550		4,050
Total unamortized deferred financing costs		(84)		(104)
Total debt		13,653		13,746
Less: current installments		(2,800)		(2,450)
Current unamortized deferred financing costs		78		78
Long-term debt	$	10,931	$	11,374

On May 2, 2017, the Company entered into a Third Amended and Restated Revolving Credit Agreement (as amended, the “Credit Agreement”) with Bank of America, as agent, and Bank of America and Brown Brothers Harriman & Co, as lenders that amended and restated the 2013 Credit Agreement. As a result of the Credit Agreement, the amounts outstanding under the 2013 Credit Agreement with maturities subsequent to March 31, 2018 are classified as long term. The Credit Agreement was entered into to, among other things, consolidate, combine and restate the outstanding indebtedness, on the date of the Credit Agreement, into a Term Loan in the principal amount of $14.0 million, and also provide for a $25.0 million revolving line of credit (the “Revolving Line”). The Term Loan and the Revolving Line each have a maturity date of May 1, 2022. Borrowings under the Term Loan accrue interest at a rate based on either the effective LIBOR for certain interest periods selected by the Company, or a daily floating rate based on the BBA LIBOR as published by Reuters (or other commercially available source providing quotations of BBA LIBOR), plus in either case, a margin of 2.75%. Additionally, the Revolving Line accrues interest at a rate based on either the effective LIBOR for certain interest periods selected by the Company, or a daily floating rate based on the BBA LIBOR, plus in either case, a margin of 2.25%.

The Term Loan and loans under the Revolving Line evidenced by the Credit Agreement, or the Loans, are guaranteed by all of the Company’s direct and indirect domestic subsidiaries, and secured by substantially all of the assets of the Company and the guarantors. The Loans are subject to restrictive covenants under the Credit Agreement, and financial covenants that require the Company and its subsidiaries to maintain certain financial ratios on a consolidated basis, including a maximum leverage, minimum fixed charge coverage and minimum working capital. Prepayment of the Loans is allowed by the Credit Agreement at any time during the terms of the Loans. The Loans also contain limitations on the Company’s ability to incur additional indebtedness and requires lender approval for acquisitions funded with cash, promissory notes and/or other consideration in excess of $6.0 million and for acquisitions funded solely with equity in excess of $10.0 million.

Derivatives

3 Months Ended

Mar. 31, 2017

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Instruments and Hedging Activities Disclosure [Text Block]

13. Derivatives

The Company uses interest-rate-related derivative instruments to manage its exposure related to changes in interest rates on its variable-rate debt instruments. The Company does not enter into derivative instruments for any purpose other than cash flow hedging. The Company does not speculate using derivative instruments.

By using derivative financial instruments to hedge exposures to changes in interest rates, the Company exposes itself to credit risk and market risk. Credit risk is the failure of the counterparty to perform under the terms of the derivative contract. When the fair value of a derivative contract is positive, the counterparty owes the Company, which creates credit risk for the Company. When the fair value of a derivative contract is negative, the Company owes the counterparty and, therefore, the Company is not exposed to the counterparty’s credit risk in those circumstances. The Company minimizes counterparty credit risk in derivative instruments by entering into transactions with carefully selected major financial institutions based upon their credit profile.

Market risk is the adverse effect on the value of a derivative instrument that results from a change in interest rates. The market risk associated with interest-rate contracts is managed by establishing and monitoring parameters that limit the types and degree of market risk that may be undertaken.

The Company assesses interest rate risk by continually identifying and monitoring changes in interest rate exposures that may adversely impact expected future cash flows and by evaluating hedging opportunities. The Company maintains risk management control systems to monitor interest rate risk attributable to both the Company’s outstanding or forecasted debt obligations as well as the Company’s offsetting hedge positions. The risk management control systems involve the use of analytical techniques, including cash flow sensitivity analysis, to estimate the expected impact of changes in interest rates on the Company’s future cash flows.

The Company uses variable-rate London Interbank Offered Rate (LIBOR) debt to finance its operations. The debt obligations expose the Company to variability in interest payments due to changes in interest rates. Management believes that it is prudent to limit the variability of a portion of its interest payments. To meet this objective, management enters into LIBOR based interest rate swap agreements to manage fluctuations in cash flows resulting from changes in the benchmark interest rate of LIBOR. These swaps change the variable-rate cash flow exposure on the debt obligations to fixed cash flows. Under the terms of the interest rate swaps, the Company receives LIBOR based variable interest rate payments and makes fixed interest rate payments, thereby creating the equivalent of fixed-rate debt for the notional amount of its debt hedged. In accordance with its Credit Agreement, the Company was required to fix the rate of interest on at least 50% of its Term Loan and the DDTL through the purchase of interest rate swaps. On June 5, 2013, the Company entered into an interest rate swap contract with an original notional amount of $15.0 million and a maturity date of March 29, 2018 in order to hedge the risk of changes in the effective benchmark interest rate (LIBOR) associated with the Company’s Term Loan. On November 29, 2013, the Company entered into a second interest rate swap contract with an original notional amount of $5.0 million and a maturity date of March 29, 2018 in order to hedge the risk of changes in the effective benchmark interest rate (LIBOR) associated with the DDTL. The notional amount of the Company’s derivative instruments as of March 31, 2017 was $4.5 million. The Term Loan swap contract effectively converted specific variable-rate debt into fixed-rate debt and fixed the LIBOR rate associated with the Term Loan at 0.96% plus a bank margin of 2.75%. The DDTL swap contract effectively converted specific variable-rate debt into fixed-rate debt and fixed the LIBOR rate associated with the Term Loan at 0.93% plus a bank margin of 2.75%.The interest rate swaps were designated as cash flow hedges in accordance with ASC 815, Derivatives and Hedging.

As disclosed in Note 12, on May 2, 2017, the Company entered into the Credit Agreement to amend its credit facility with Bank of America, as agent, and Bank of America and Brown Brothers Harriman & Co. as lenders. Immediately after entering into this Credit Agreement, the Company entered into a new interest rate swap contract with Bank of America with a notional amount of $14.0 million and a maturity date of March 30, 2022 in order to hedge the risk of changes in the effective benchmark interest rate (LIBOR) associated with the Company’s Term Loan. The swap contract converted specific variable-rate debt into fixed-rate debt and fixed the LIBOR rate associated with the Term Loan at 1.86%. The interest rate swap was designated as a cash flow hedge instrument in accordance with ASC 815 “Derivatives and Hedging”. As a result of entering into the new interest rate swap contract, the Company unwound the previous interest rate swap contracts, and received an immaterial amount in proceeds.

The following table presents the notional amount and fair value of the Company’s derivative instruments as of March 31, 2017 and December 31, 2016.


				March 31, 2017		March 31, 2017
				Notional Amount		Fair Value (a)
Derivatives designated as hedging instruments under ASC 815		Balance sheet classification		(in thousands)
Interest rate swaps		Other liabilities-non current	$	4,500	$	7


				December 31, 2016		December 31, 2016
				Notional Amount		Fair Value (a)
Derivatives designated as hedging instruments under ASC 815		Balance sheet classification		(in thousands)
Interest rate swaps		Other liabilities-non current	$	5,500	$	-

	(a) See Note 14 for the fair value measurements related to these financial instruments.

All of the Company’s derivative instruments are designated as hedging instruments.

The Company has structured its interest rate swap agreements to be 100% effective and as a result, there was no impact to earnings resulting from hedge ineffectiveness. Changes in the fair value of interest rate swaps designated as hedging instruments that effectively offset the variability of cash flows associated with variable-rate, long-term debt obligations are reported in accumulated other comprehensive income (“AOCI”). These amounts subsequently are reclassified into interest expense as a yield adjustment of the hedged interest payments in the same period in which the related interest affects earnings. The Company’s interest rate swap agreement was deemed to be fully effective in accordance with ASC 815, and, as such, unrealized gains and losses related to these derivatives were recorded as AOCI.

The following table summarizes the effect of derivatives designated as cash flow hedging instruments and their classification within comprehensive loss for the three months ended March 31, 2017 and 2016:

Derivatives in Hedging Relationships	Amount of gain (loss) recognized in OCI on derivative (effective portion)
	Three Months Ended March 31,
	2017		2016
	(in thousands)
Interest rate swaps	$	4	$	(36)

The following table summarizes the reclassifications out of accumulated other comprehensive loss for the three months ended March 31, 2017 and 2016:

Details about AOCI Components	Amount reclassified from AOCI into income (effective portion)				Location of amount
	Three Months Ended March 31,				reclassified from AOCI
	2017		2016		into income (effective portion)
	(in thousands)
Interest rate swaps	$	3	$	13	Interest expense

As of March 31, 2017, $7 thousand of deferred losses on derivative instruments accumulated in AOCI are expected to be reclassified to earnings during the next twelve months. Transactions and events expected to occur over the next twelve months that will necessitate reclassifying these derivatives’ losses to earnings include the repricing of variable-rate debt. There were no cash flow hedges discontinued during 2017 or 2016

- Definition

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41620-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624163-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5579240-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624177-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80784-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41641-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5579245-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624258-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80748-113994

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5708775-113959

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5708773-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5618551-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5580258-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624181-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41638-113959

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Fair Value Measurements

3 Months Ended

Mar. 31, 2017

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

14. Fair Value Measurements

Fair value measurement is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy is established, which prioritizes the inputs used in measuring fair value into three broad levels as follows:

Level 1—Quoted prices in active markets for identical assets or liabilities.

Level 2—Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.

Level 3—Unobservable inputs based on the Company’s own assumptions.

The following tables present the fair value hierarchy for those liabilities measured at fair value on a recurring basis:

	Fair Value as of March 31, 2017
(In thousands)		Level 1		Level 2		Level 3		Total
Liabilities:
Interest rate swap agreements	$	-	$	7	$	-	$	7


	Fair Value as of December 31, 2016
(In thousands)		Level 1		Level 2		Level 3		Total
Liabilities:
Interest rate swap agreements	$	-	$	-	$	-	$	-

The Company uses the market approach technique to value its financial liabilities. The Company’s financial liabilities carried at fair value include derivative instruments used to hedge the Company’s interest rate risks. The fair value of the Company’s interest rate swap agreements was based on LIBOR yield curves at the reporting date.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Leases

3 Months Ended

Mar. 31, 2017

Leases Disclosure [Abstract]

Leases Disclosure [Text Block]

10. Leases

The Company has noncancelable operating leases for office and warehouse space expiring at various dates through 2022 and thereafter. Rent expense, which is recorded on a straight-line basis, is estimated to be $1.7 million for the year ended December 31, 2017. Rent expense was approximately $0.4 million and $0.5 million for the three months ended March 31, 2017 and 2016, respectively.

Future minimum lease payments for operating leases, with initial or remaining terms in excess of one year at March 31, 2017, are as follows:

		Operating
		Leases
		(in thousands)
2018	$	1,610
2019		1,618
2020		1,421
2021		1,098
2022		1,098
Thereafter		1,836
Net minimum lease payments	$	8,681

- Definition

Tabular disclosure of a lessee's leasing arrangements including: (1) the basis on which contingent rental payments are determined, (2) the existence and terms of renewal or purchase options and escalation clauses, (3) restrictions imposed by lease arrangements, such as those concerning dividends, additional debt, and further leasing, (4) rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions. Disclosure may also include the specific period used to amortize material leasehold improvements made at the inception of the lease or during the lease term. Additionally, for operating leases having initial or remaining noncancelable lease terms in excess of one year: (a) future minimum rental payments required as of the date of the latest balance sheet presented, in the aggregate and for each of the five succeeding fiscal years, (b) the total of minimum rentals to be received in the future under noncancelable subleases as of the date of the latest balance sheet presented, and (c) for all operating leases, rental expense for each period for which an income statement is presented, with separate amounts for minimum rentals, contingent rentals, and sublease rentals. Rental payments under leases with terms of a month or less that were not renewed need not be included.

+ References + Details

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2017
Income Tax [Abstract]
Income Taxes Disclosure [Text Block]	15. Income Tax Income tax was an expense of approximately $23 thousand and $0.2 million for the three months ended March 31, 2017 and 2016, respectively. The tax expense for the three months ended March 31, 2017 reflects the expense recorded for the three months ended March 31, 2017 associated with the actual results for the three-month period, as described below. Discrete items included in the tax expense for the three months ended March 31, 2017 included changes to reserves for uncertain tax positions and tax deficiencies related to stock-based compensation. Tax expense for the three months ended March 31, 2016 included foreign currency gains and losses and the tax impact of the amortization of certain indefinite-lived intangible assets which are amortized for tax purposes only, against which a valuation allowance is not established. The effective income tax rate was (2.2%) for the three months ended March 31, 2017, compared with (43.6%) for the same period in 2016. The tax rates for the three months ended March 31, 2017 and 2016 were based on actual results for the three-month period rather than an effective tax rate estimated for the entire year. In 2017 and 2016 the Company determined that using a year-to-date approach resulted in a better estimate of income tax expense/benefit based on its forecast of pre-tax income/loss, the mix of taxable income/loss across several jurisdictions with different statutory tax rates, and the impact of the full valuation allowance against U.S. deferred tax assets. The difference between the Company’s effective tax rate period over period was primarily attributable to higher pre-tax income at certain individual subsidiaries in 2016 versus 2017, despite an overall pre-tax loss in both periods. In addition, both periods included the tax impact of amortization of certain indefinite-lived intangibles which are amortized for tax purposes only, against which a valuation allowance is not established.

Employee Benefit Plans

3 Months Ended

Mar. 31, 2017

Employee Benefit Plans Disclosure [Abstract]

Employee Benefit Plans Disclosure [Text Block]

9. Employee Benefit Plans

One of the Company’s subsidiaries in the United Kingdom, or UK, Biochrom Limited, maintains contributory, defined benefit pension plans for substantially all of its employees. As of June 30, 2014, these defined benefit pension plans were closed to new employees, as well as closed to the future accrual of benefits for existing employees. The components of the Company’s defined benefit pension expense were as follows:

		Three Months Ended
		March 31,
		2017		2016
		(in thousands)
Components of net periodic benefit cost:
Interest cost	$	125	$	168
Expected return on plan assets		(159)		(181)
Net amortization loss		87		80
Net periodic benefit cost	$	53	$	67

For the three months ended March 31, 2017 and 2016, the Company contributed $0.2 million, for both periods, to its defined benefit pension plans. The Company expects to contribute approximately $0.5 million to its defined benefit pension plans during the remainder of 2017.

The Company had an underfunded pension liability of approximately $3.2 million and $3.0 million, as of March 31, 2017 and December 31, 2016, respectively, included in the other long term liabilities line item in the consolidated balance sheets.

Capital Stock

3 Months Ended

Mar. 31, 2017

Capital Stock Disclosure [Abstract]

Capital Stock Disclosure [Text Block]

11. Capital Stock

Common Stock

On February 5, 2008, the Company’s Board of Directors adopted a Shareholder Rights Plan and declared a dividend distribution of one preferred stock purchase right for each outstanding share of the Company’s common stock to shareholders of record as of the close of business on February 6, 2008. Initially, these rights will not be exercisable and will trade with the shares of the Company’s common stock. Under the Shareholder Rights Plan, the rights generally will become exercisable if a person becomes an “acquiring person” by acquiring 20% or more of the common stock of the Company or if a person commences a tender offer that could result in that person owning 20% or more of the common stock of the Company. If a person becomes an acquiring person, each holder of a right (other than the acquiring person) would be entitled to purchase, at the then-current exercise price, such number of shares of preferred stock which are equivalent to shares of the Company’s common stock having a value of twice the exercise price of the right. Unless the Board of Directors elects to extend such plan, the Shareholder Rights Plan will expire in February 2018. If the Company is acquired in a merger or other business combination transaction after any such event, each holder of a right would then be entitled to purchase, at the then-current exercise price, shares of the acquiring company’s common stock having a value of twice the exercise price of the right.

Preferred Stock

The Company’s Board of Directors has the authority to issue up to 5.0 million shares of preferred stock and to determine the price privileges and other terms of the shares. The Board of Directors may exercise this authority without any further approval of stockholders. As of March 31, 2017, the Company had no preferred stock issued or outstanding.

Employee Stock Purchase Plan (as amended, the “ESPP”)

In 2000, the Company approved the ESPP. Under this ESPP, participating employees can authorize the Company to withhold a portion of their base pay during consecutive six-month payment periods for the purchase of shares of the Company’s common stock. At the conclusion of the period, participating employees can purchase shares of the Company’s common stock at 85% of the lower of the fair market value of the Company’s common stock at the beginning or end of the period. Shares are issued under the ESPP for the six-month periods ending June 30 and December 31. Under this plan, 750,000 shares of common stock are authorized for issuance of which 725,239 shares were issued as of March 31, 2017. There were no shares issued under the ESPP during the three months ended March 31, 2017 and 2016.

Stock Option and Equity Incentive Plans

Third Amended and Restated 2000 Stock Option and Incentive Plan (as amended, the “Third A&R Plan”)

The Second Amendment to the Third A&R Plan (the “Amendment”) was adopted by the Board of Directors on April 3, 2015. Such Amendment was approved by the stockholders at the Company’s 2015 Annual Meeting of Stockholders. Pursuant to the Amendment, the aggregate number of shares authorized for issuance under the Third A&R Plan was increased by 2,500,000 shares to 17,508,929.

Restricted Stock Units with a Market Condition (the “Market Condition RSU’s”)

On August 3, 2015, the Compensation Committee of the Board of Directors of the Company approved and granted deferred stock awards of Market Condition RSU’s to certain members of the Company’s management team under the Third A&R Plan. The vesting of these Market Condition RSU’s is cliff-based and linked to the achievement of a relative total shareholder return of the Company’s common stock from August 3, 2015 to the earlier of (i) August 3, 2018 or (ii) upon a change of control (measured relative to the Russell 3000 index and based on the 20-day trading average price before each such date). As of March 31, 2017, the target number of these restricted stock units that may be earned is 182,150 shares; the maximum amount is 150% of the target number.

Stock-Based Payment Awards

The Company accounts for stock-based payment awards in accordance with the provisions of FASB ASC 718, which requires it to recognize compensation expense for all stock-based payment awards made to employees and directors including stock options, restricted stock units, Market Condition RSU’s and employee stock purchases related to the ESPP.

The Company adopted ASU 2016-09 as of January 1, 2017. As disclosed in footnote 2, as a result of this adoption, the Company has elected as an accounting policy to account for forfeitures for service based awards as they occur, with no adjustment for estimated forfeitures. The Company recognized as of January 1, 2017, a cumulative effect adjustment of $0.1 million to reduce retained earnings as required under the modified retrospective approach.

Stock option and restricted stock unit activity under the Company’s Third A&R Plan for the three months ended March 31, 2017 was as follows:

		Stock Options			Restricted Stock Units			Market Condition RSU's
				Weighted
		Stock		Average	Restricted			Market
		Options		Exercise	Stock Units		Grant Date	Condition RSU's		Grant Date
		Outstanding		Price	Outstanding		Fair Value	Outstanding		Fair Value

Balance at December 31, 2016		4,096,818	$	3.94	1,072,653	$	3.15	182,150	$	4.81
	Granted	30,000		3.25	445,690		2.83	-		-
	Exercised	(5,709)		2.56	-		-	-		-
	Vested (RSUs)	-		-	(251,570)		3.28	-		-
	Cancelled / forfeited	(152,212)		3.68	(4,190)		3.05	-		-
Balance at March 31, 2017		3,968,897	$	3.94	1,262,583	$	3.01	182,150	$	4.81

The weighted average fair value of the options granted under the Third A&R Plan during the three months ended March 31, 2017 and 2016 was $1.27 and $1.11, respectively. The following assumptions were used to estimate the fair value, using the Black-Scholes option pricing model, of stock options granted during the three months ended March 31, 2017 and 2016:

	Three Months Ended
	March 31,
	2017		2016
Volatility	41.07	%	40.26	%
Risk-free interest rate	1.89	%	1.48	%
Expected holding period (in years)	5.20	years	5.36	years
Dividend yield	-	%	-	%

The Company used historical volatility to calculate the expected volatility for each grant as of the grant date. Historical volatility was determined by calculating the mean reversion of the daily adjusted closing stock price. The risk-free interest rate assumption is based upon observed U.S. Treasury bill interest rates (risk-free) appropriate for the term of the Company’s stock options and Market Condition RSU’s. The expected holding period of stock options represents the period of time options are expected to be outstanding and is based on historical experience. The vesting period ranges from one to four years and the contractual life is ten years. The correlation coefficient, used to value the Market Condition RSU’s, represents the way in which entities move in relation to the Russell 3000 index as a whole.

Stock-based compensation expense related to stock options, restricted stock units, Market Condition RSU’s and the ESPP for the three months ended March 31, 2017 and 2016 was allocated as follows:

		Three Months Ended
		March 31,
		2017		2016
		(in thousands)

Cost of revenues	$	13	$	11
Sales and marketing		133		101
General and administrative		688		622
Research and development		29		20
Total stock-based compensation	$	863	$	754

The Company did not capitalize any stock-based compensation.

Earnings per share

Basic earnings per share is based upon net income divided by the number of weighted average common shares outstanding during the period. The calculation of diluted earnings per share assumes conversion of stock options, restricted stock units and Market Condition RSU’s into common stock using the treasury method. The weighted average number of shares used to compute basic and diluted earnings per share consists of the following:

	Three Months Ended
	March 31,
	2017	2016

Basic	34,579,473	34,013,352
Effect of assumed conversion of employee and director stock options, restricted stock units and Market Condition RSU's	-	-
Diluted	34,579,473	34,013,352

Excluded from the shares used in calculating the diluted earnings per common share in the above table are options, restricted stock units and Market Condition RSU’s of approximately 5,413,630 and 5,461,017 shares of common stock for the three months ended March 31, 2017 and 2016, respectively, as the impact of these shares would be anti-dilutive.

Related Party Transactions	3 Months Ended
Related Party Transactions	Mar. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	7. Related Party Transactions As part of the acquisitions of Multi Channel Systems MCS GmbH (MCS) and Triangle BioSystems, Inc. (TBSI) in 2014, the Company signed lease agreements with the former owners of the acquired companies. The principals of such former owners of MCS and TBSI were employees of the Company as of March 31, 2017 and 2016. Pursuant to a lease agreement, the Company incurred rent expense of approximately $58 thousand to the former owners of MCS for both the three months ended March 31, 2017 and 2016, respectively. The Company incurred rent expense of approximately $11 thousand to the former owner of TBSI for both the three months ended March 31, 2017 and 2016, respectively

Warranties

3 Months Ended

Mar. 31, 2017

Warranties Disclosure [Abstract]

Warranties Disclosure [Text Block]

8. Warranties

Warranties are estimated and accrued at the time revenues are recorded. A rollforward of the Company’s product warranty accrual is as follows:

		Beginning		Additions/		Ending
		Balance	Payments	(Credits)		Balance
		(in thousands)

Year ended December 31, 2016	$	147	(97)	143	$	193

Three months ended March 31, 2017	$	193	(3)	16	$	206

Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2017
Subsequent Events [Abstract]
Subsequent Events [Text Block]	16. Subsequent Events On April 14, 2017, anticipated representatives for the estate of an individual plaintiff filed a wrongful death complaint with the Suffolk Superior Court, in the County of Suffolk, Massachusetts, against the Company and other defendants, including Biostage, Inc. (f/k/a Harvard Apparatus Regenerative Technology, Inc.), its subsidiary that was spun off in 2013, as well as another third party. The complaint seeks payment for an unspecified amount of damages and alleges that the plaintiff sustained terminal injuries allegedly caused by products, including synthetic trachea scaffolds and bioreactors, provided by certain of the named defendants and utilized in connection with surgeries performed by third parties in 2012 and 2013. The litigation is at an early stage and the Company intends to vigorously defend this case. While the Company believe that such claim is without merit, the Company is unable to predict the ultimate outcome of such litigation. On May 2, 2017, the Company entered into the Credit Agreement which restated the 2013 Agreement. See Note 12 for a discussion of the Credit Agreement. Additionally, immediately after entering into the Credit Agreement, the Company entered into a new interest swap agreement with Bank of America. See Note 13 for a discussion of the interest swap agreement

Summary of Significant Accounting Policies (Policies)	3 Months Ended
Summary of Significant Accounting Policies (Policies)	Mar. 31, 2017
Recently Issued Accounting Pronouncements [Abstract]
Recently Issued Accounting Pronouncements Disclosure [Text Block]	2. Recently Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, “Revenue from Contracts with Customers,” a new accounting standard that provides for a comprehensive model to use in the accounting for revenue arising from contracts with customers that will replace most existing revenue recognition guidance within generally accepted accounting principles in the United States. Under this standard, revenue will be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The Company expects to adopt this standard as of January 1, 2018 using the modified retrospective approach. The Company intends to complete a comprehensive assessment of its contracts in 2017 concerning any unique customer contract terms or transactions that could have implications to the timing of revenue recognition under the new guidance. The Company expects this undertaking will be complete in the second half of 2017. In February 2016, the FASB issued ASU 2016-02, Leases, which is intended to improve financial reporting about leasing transactions. The update requires a lessee to record on the balance sheet the assets and liabilities for the rights and obligations created by lease terms of more than 12 months. The update is effective for fiscal years beginning after December 15, 2018. The Company is evaluating the requirements of this guidance and has not yet determined the impact of the adoption on its consolidated financial position, results of operations and cash flows, however, assets and liabilities will increase upon adoption for right-of-use assets and lease liabilities. The Company’s future commitments under lease obligations are summarized in Note 10. Recently Adopted Accounting Pronouncements In March 2016, the FASB issued ASU 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which simplifies the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. The standard requires an entity to recognize all excess tax benefits and tax deficiencies as income tax benefit or expense in the income statement as discrete items in the reporting period in which they occur, and such tax benefits and tax deficiencies are not included in the estimate of an entity’s annual effective tax rate, applied on a prospective basis. Further, the standard eliminates the requirement to defer the recognition of excess tax benefits until the benefit is realized through a reduction to taxes payable. All excess tax benefits previously unrecognized, along with any valuation allowance, should be recognized on a modified retrospective basis as a cumulative adjustment to retained earnings as of the date of adoption. Under ASU 2016-09, an entity that applies the treasury stock method in calculating diluted earnings per share is required to exclude excess tax benefits and deficiencies from the calculation of assumed proceeds since such amounts are recognized in the income statement. Excess tax benefits should also be classified as operating activities in the same manner as other cash flows related to income taxes on the statement of cash flows, as such excess tax benefits no longer represent financing activities since they are recognized in the income statement, and should be applied prospectively or retrospectively to all periods presented. The Company adopted ASU 2016-09 as of January 1, 2017. The Company recorded a cumulative increase in retained earnings of $0.5 million at the beginning of the first quarter of 2017 with a corresponding increase in deferred tax assets related to the prior years’ unrecognized excess tax benefits. An equal amount of valuation allowance was also recorded against these deferred tax assets with a corresponding decrease to retained earnings resulting in a net impact of $0. In addition, tax deficiencies related to vested restricted stock units and canceled stock options during the first quarter of 2017 have been recognized in the current period’s income statement. ASU 2016-09 also allows an entity to elect as an accounting policy either to continue to estimate the total number of awards for which the requisite service period will not be rendered or to account for forfeitures for service based awards as they occur. An entity that elects to account for forfeitures as they occur should apply the accounting change on a modified retrospective basis as a cumulative effect adjustment to retained earnings as of the date of adoption. The Company elected as an accounting policy to account for forfeitures for service based awards as they occur, and as a result, the Company recorded a cumulative effect adjustment of $0.1 million to reduce retained earnings with a corresponding increase in additional paid in capital related to the prior years’ stock-based compensation expense as required under the modified retrospective approach. The tax effect of this adjustment, which included the impact of a valuation allowance was immaterial.

Accumulated Other Comprehensive Income (Tables)

3 Months Ended

Mar. 31, 2017

Accumulated Other Comprehensive Income [Abstract]

Accumulated Other Comprehensive Income [Table Text Block]

		Foreign currency		Derivatives
		translation		qualifying as		Defined benefit
(in thousands)		adjustments		hedges		pension plans		Total

Balance at December 31, 2016	$	(14,200)	$	-	$	(2,458)	$	(16,658)

Other comprehensive income before reclassifications		942		4		-		946
Amounts reclassified from AOCI		-		3		-		3

Other comprehensive income		942		7		-		949

Balance at March 31, 2017	$	(13,258)	$	7	$	(2,458)	$	(15,709)

Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]

Details about AOCI Components	Amount reclassified from AOCI into income (effective portion)				Location of amount
	Three Months Ended March 31,				reclassified from AOCI
	2017		2016		into income (effective portion)
	(in thousands)
Interest rate swaps	$	3	$	13	Interest expense

Goodwill and Other Intangible Assets (Tables)

3 Months Ended

Mar. 31, 2017

Goodwill And Other Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets and Goodwill [Table Text Block]

									Weighted
									Average
		March 31, 2017				December 31, 2016			Life	(a)
		(in thousands)
Amortizable intangible assets:		Gross		Accumulated Amortization		Gross		Accumulated Amortization
Existing technology	$	15,287	$	(12,020)	$	15,082	$	(11,710)	6.8	Years
Trade names		7,436		(3,617)		7,379		(3,479)	7.8	Years
Distribution agreements/customer relationships		23,136		(13,228)		22,976		(12,862)	8.7	Years
Patents		207		(131)		204		(119)	1.9	Years
Total amortizable intangible assets		46,066	$	(28,996)		45,641	$	(28,170)

Indefinite-lived intangible assets:
Goodwill		38,398				38,032
Other indefinite-lived intangible assets		1,216				1,209
Total goodwill and other indefinite-lived intangible assets		39,614				39,241

Total intangible assets, gross	$	85,680			$	84,882

(a) Weighted average life as of March 31, 2017.

Goodwill Rollforward [Table Text Block]

			(in thousands)
Balance at December 31, 2016		$	38,032
	Effect of change in currency translation		366
Balance at March 31, 2017		$	38,398

Inventories (Tables)

3 Months Ended

Mar. 31, 2017

Inventories Disclosure [Abstract]

Schedule of Inventory [Table Text Block]

			March 31,		December 31,
			2017		2016
			(in thousands)
Finished goods		$	9,686	$	9,340
Work in process			900		823
Raw materials			9,696		9,792
	Total	$	20,282	$	19,955

Property, Plant and Equipment (Tables)

3 Months Ended

Mar. 31, 2017

Property, Plant and Equipment Disclosure [Abstract]

Schedule Of Property Plant And Equipment [Table Text Block]

		March 31,		December 31,
		2017		2016
		(in thousands)
Land, buildings and leasehold improvements	$	2,117	$	2,095
Machinery and equipment		7,395		7,224
Computer equipment and software		8,345		8,115
Furniture and fixtures		1,284		1,274
Automobiles		201		196
		19,342		18,904
Less: accumulated depreciation		(15,074)		(14,608)
Property, plant and equipment, net	$	4,268	$	4,296

Long Term Debt (Tables)

3 Months Ended

Mar. 31, 2017

Long Term Debt Disclosure [Abstract]

Schedule of Debt [Table Text Block]

		March 31,		December 31,
		2017		2016
		(in thousands)
Long-term debt:
Term loan	$	5,062	$	5,400
DDTL		4,125		4,400
Revolving line		4,550		4,050
Total unamortized deferred financing costs		(84)		(104)
Total debt		13,653		13,746
Less: current installments		(2,800)		(2,450)
Current unamortized deferred financing costs		78		78
Long-term debt	$	10,931	$	11,374

Derivative (Tables)

3 Months Ended

Mar. 31, 2017

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]


				March 31, 2017		March 31, 2017
				Notional Amount		Fair Value (a)
Derivatives designated as hedging instruments under ASC 815		Balance sheet classification		(in thousands)
Interest rate swaps		Other liabilities-non current	$	4,500	$	7


				December 31, 2016		December 31, 2016
				Notional Amount		Fair Value (a)
Derivatives designated as hedging instruments under ASC 815		Balance sheet classification		(in thousands)
Interest rate swaps		Other liabilities-non current	$	5,500	$	-

	(a) See Note 14 for the fair value measurements related to these financial instruments.

Schedule of Cash Flow Hedges Included in AOCI [Table Text Block]

Derivatives in Hedging Relationships	Amount of gain (loss) recognized in OCI on derivative (effective portion)
	Three Months Ended March 31,
	2017		2016
	(in thousands)
Interest rate swaps	$	4	$	(36)

Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]

Details about AOCI Components	Amount reclassified from AOCI into income (effective portion)				Location of amount
	Three Months Ended March 31,				reclassified from AOCI
	2017		2016		into income (effective portion)
	(in thousands)
Interest rate swaps	$	3	$	13	Interest expense

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2017

Fair Value Disclosures [Abstract]

Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis [Table Text Block]

	Fair Value as of March 31, 2017
(In thousands)		Level 1		Level 2		Level 3		Total
Liabilities:
Interest rate swap agreements	$	-	$	7	$	-	$	7


	Fair Value as of December 31, 2016
(In thousands)		Level 1		Level 2		Level 3		Total
Liabilities:
Interest rate swap agreements	$	-	$	-	$	-	$	-

Leases (Tables)

3 Months Ended

Mar. 31, 2017

Leases Disclosure [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

		Operating
		Leases
		(in thousands)
2018	$	1,610
2019		1,618
2020		1,421
2021		1,098
2022		1,098
Thereafter		1,836
Net minimum lease payments	$	8,681

Employee Benefit Plans (Tables)

3 Months Ended

Mar. 31, 2017

Employee Benefit Plans Disclosure [Abstract]

Schedule of Changes in Projected Benefit Obligations [Table Text Block]

		Three Months Ended
		March 31,
		2017		2016
		(in thousands)
Components of net periodic benefit cost:
Interest cost	$	125	$	168
Expected return on plan assets		(159)		(181)
Net amortization loss		87		80
Net periodic benefit cost	$	53	$	67

Capital Stock (Tables)

3 Months Ended

Mar. 31, 2017

Capital Stock Disclosure [Abstract]

Schedule Of Stock Options And Restricted Stock Units Activity Rollforward [Table Text Block]

		Stock Options			Restricted Stock Units			Market Condition RSU's
				Weighted
		Stock		Average	Restricted			Market
		Options		Exercise	Stock Units		Grant Date	Condition RSU's		Grant Date
		Outstanding		Price	Outstanding		Fair Value	Outstanding		Fair Value

Balance at December 31, 2016		4,096,818	$	3.94	1,072,653	$	3.15	182,150	$	4.81
	Granted	30,000		3.25	445,690		2.83	-		-
	Exercised	(5,709)		2.56	-		-	-		-
	Vested (RSUs)	-		-	(251,570)		3.28	-		-
	Cancelled / forfeited	(152,212)		3.68	(4,190)		3.05	-		-
Balance at March 31, 2017		3,968,897	$	3.94	1,262,583	$	3.01	182,150	$	4.81

Table Of Assumptions [Table Text Block]

	Three Months Ended
	March 31,
	2017		2016
Volatility	41.07	%	40.26	%
Risk-free interest rate	1.89	%	1.48	%
Expected holding period (in years)	5.20	years	5.36	years
Dividend yield	-	%	-	%

Stock Based Compensation Expense Activity By Function [Table Text Block]

		Three Months Ended
		March 31,
		2017		2016
		(in thousands)

Cost of revenues	$	13	$	11
Sales and marketing		133		101
General and administrative		688		622
Research and development		29		20
Total stock-based compensation	$	863	$	754

Basic and Diluted Shares [Table Text Block]

	Three Months Ended
	March 31,
	2017	2016

Basic	34,579,473	34,013,352
Effect of assumed conversion of employee and director stock options, restricted stock units and Market Condition RSU's	-	-
Diluted	34,579,473	34,013,352

Warranties (Tables)

3 Months Ended

Mar. 31, 2017

Warranties Disclosure [Abstract]

Warranty Rollforward Disclosure [Table Text Block]

		Beginning		Additions/		Ending
		Balance	Payments	(Credits)		Balance
		(in thousands)

Year ended December 31, 2016	$	147	(97)	143	$	193

Three months ended March 31, 2017	$	193	(3)	16	$	206

Summary of Significant Accounting Policy (Details 1)	3 Months Ended
Summary of Significant Accounting Policy (Details 1)	Mar. 31, 2017
Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Weighted Average Useful Life	6 years 9 months 18 days
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Weighted Average Useful Life	7 years 9 months 18 days
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Weighted Average Useful Life	8 years 8 months 12 days
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Weighted Average Useful Life	1 year 10 months 25 days

Accumulated Other Comprehensive Income (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2017 USD ($)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Opening Balance	$ (16,658)
Other Comprehensive Income (Loss) before Reclassifications	946
Reclassification from Accumulated Other Comprehensive Income	3
Other Comprehensive Income (Loss), Net of Tax, total	949
Closing Balance	(15,709)
Foreign currency translation adjustments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Opening Balance	(14,200)
Other Comprehensive Income (Loss) before Reclassifications	942
Reclassification from Accumulated Other Comprehensive Income	0
Other Comprehensive Income (Loss), Net of Tax, total	942
Closing Balance	(13,258)
Derivatives qualifying as hedges
Accumulated Other Comprehensive Income (Loss) [Line Items]
Opening Balance	0
Other Comprehensive Income (Loss) before Reclassifications	4
Reclassification from Accumulated Other Comprehensive Income	3
Other Comprehensive Income (Loss), Net of Tax, total	7
Closing Balance	7
Defined benefit pension plans
Accumulated Other Comprehensive Income (Loss) [Line Items]
Opening Balance	(2,458)
Other Comprehensive Income (Loss) before Reclassifications	0
Reclassification from Accumulated Other Comprehensive Income	0
Other Comprehensive Income (Loss), Net of Tax, total	0
Closing Balance	$ (2,458)

Goodwill and Other Intangible Assets (Narratives) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Goodwill And Other Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 599	$ 680
Estimated Amortization Expense Next Twelve Months	2,400
Estimated Amortization Expense Year 2	2,300
Estimated Amortization Expense Year 3	2,100
Estimated Amortization Expense Year 4	2,100
Estimated Amortization Expense Year 5	$ 2,100

Goodwill and Other Intangible Assets (Details 1) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 46,066	$ 45,641
Finite-Lived Intangible Assets, Accumulated Amortization	(28,996)	(28,170)
Goodwill	38,398	38,032
Other indefinite lived intangible assets	1,216	1,209
Total goodwill and other indefinite lived intangible assets	39,614	39,241
Total intangible assets	85,680	84,882
Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	15,287	15,082
Finite-Lived Intangible Assets, Accumulated Amortization	$ (12,020)	(11,710)
Finite-Lived Intangible Assets, Weighted Average Useful Life	6 years 9 months 18 days
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 7,436	7,379
Finite-Lived Intangible Assets, Accumulated Amortization	$ (3,617)	(3,479)
Finite-Lived Intangible Assets, Weighted Average Useful Life	7 years 9 months 18 days
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 23,136	22,976
Finite-Lived Intangible Assets, Accumulated Amortization	$ (13,228)	(12,862)
Finite-Lived Intangible Assets, Weighted Average Useful Life	8 years 8 months 12 days
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 207	204
Finite-Lived Intangible Assets, Accumulated Amortization	$ (131)	$ (119)
Finite-Lived Intangible Assets, Weighted Average Useful Life	1 year 10 months 25 days

Goodwill and Other Intangible Assets (Details 2) $ in Thousands	3 Months Ended
	Mar. 31, 2017 USD ($)
Goodwill And Other Intangible Assets Disclosure [Abstract]
Goodwill, Beginning Balance	$ 38,032
Effect of change in currency transaltion	366
Goodwill, Ending Balance	$ 38,398

Inventories (Details 1) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Inventories Disclosure [Abstract]
Finished Goods	$ 9,686	$ 9,340
Work in Process	900	823
Raw Materials	9,696	9,792
Total Inventories, Net	$ 20,282	$ 19,955

Property, Plant and Equipment (Details 1) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 19,342	$ 18,904
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	(15,074)	(14,608)
Property, plant and equipment, net	4,268	4,296
Land, Buildings and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	2,117	2,095
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	7,395	7,224
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	8,345	8,115
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	1,284	1,274
Automobiles [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 201	$ 196

Restructuring and Other Exit Cots (Narratives) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Restructuring Cost and Reserve [Line Items]
Restructuring charges (credits)	$ 0	$ 11

Restructuring and Other Exit Costs (Details 1) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Restructuring Reserve [Roll Forward]
Restructuring charges (credits)	$ 0	$ 11

Long Term Debt (Narratives) (Details) - USD ($) $ in Thousands						3 Months Ended
	May 02, 2017	Apr. 24, 2015	Oct. 31, 2013	Mar. 29, 2013	Aug. 07, 2009	Mar. 31, 2017	Dec. 31, 2016
Credit Agreement [Line Items]
Previous Approved Credit Facility					$ 20,000
Secured Debt						$ 13,653	$ 13,746
Line of Credit Facility, Maximum Borrowing Capacity				$ 50,000
Minimum percentage of Term Loan and the DDTL that company was required to fix the rate of interest on						50.00%
Line of Credit Facility, Remaining Borrowing Capacity						$ 5,200
Interest Rate In Excess Of LIBOR On Credit Facility					3.00%
DDTL Threshold For Dollar For Dollar Reduction In Revolving Line				10,000
Transfer Of Delayed Draw Down Term Loan Capacity To Revolver Capacity			$ 5,000
Lender Approval To Fund Acquisition With Cash Promissory Note In Excess Of Threshold	$ 6,000					6,000
Lender Approval To Fund Acquisition With Equity In Excess Of Threshold	10,000					$ 10,000
Revolving Credit Facility [Member]
Credit Agreement [Line Items]
Secured Debt	$ 25,000			$ 25,000
Maturity Dates	May 01, 2022			Mar. 29, 2018
Basis Spread Over LIBOR	2.25%	2.25%
Interest Rate As Of Reporting Date						3.23%
Term Loan [Member]
Credit Agreement [Line Items]
Secured Debt	$ 14,000			$ 15,000
Maturity Dates	May 01, 2022			Mar. 29, 2018
Basis Spread Over LIBOR	2.75%	2.75%
Interest Rate As Of Reporting Date						3.96%
Delayed Drawdown Term Loan [Member]
Credit Agreement [Line Items]
Secured Debt				$ 15,000
Maturity Dates				Mar. 29, 2018
Basis Spread Over LIBOR		2.75%
Maximum Borrowings Available Under The Current Credit Agreement			$ 10,000
Interest Rate As Of Reporting Date						3.83%

Long Term Debt (Details 1) - USD ($) $ in Thousands	May 02, 2017	Mar. 31, 2017	Dec. 31, 2016	Mar. 29, 2013
Debt Instrument
Term Loan		$ 5,062	$ 5,400
DDTL		4,125	4,400
Revolving Credit Facility		4,550	4,050
Total unamortized deferred financing costs		(84)	(104)
Total Debt		13,653	13,746
Less: current installments		(2,722)	(2,372)
Long-term debt		$ 10,931	$ 11,374
Term Loan
Debt Instrument
Total Debt	$ 14,000			$ 15,000
DDTL
Debt Instrument
Total Debt				15,000
Revolving line
Debt Instrument
Total Debt	$ 25,000			$ 25,000

Derivative (Narratives) (Details) - USD ($)		3 Months Ended
Derivative (Narratives) (Details) - USD ($)	May 02, 2017	Mar. 31, 2017	Nov. 30, 2013	Jun. 05, 2013
Derivative Instruments And Hedging Activities Disclosure [Line Items]
Minimum percentage of Term Loan and the DDTL that company was required to fix the rate of interest on		50.00%
Deferred losses on derivative instruments accumulated in AOCI expected to be reclassified to earnings		$ 7,000
Derivative Interest Rate Swap Effective Percentage		100.00%
Delayed Drawdown Term Loan [Member]
Derivative Instruments And Hedging Activities Disclosure [Line Items]
Notional Amount of Interest Rate Swaps			$ 5,000,000
LIBOR Fixed Rate		0.93%
Term Loan [Member]
Derivative Instruments And Hedging Activities Disclosure [Line Items]
Notional Amount of Interest Rate Swaps	$ 14,000,000			$ 15,000,000
LIBOR Fixed Rate	1.86%	0.96%

Derivative (Details 1) - Other liabilities-non current [Member] - Derivatives qualifying as hedges [Member] - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Derivatives, Fair Value [Line Items]
Notional Amount of Interest Rate Derivatives	$ 4,500	$ 5,500
Derivative Liability, Fair Value, Net	$ 7	$ 0

Derivative (Details 2) - Derivatives qualifying as hedges [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Loss Recognized in Other Comprehensive Income (Loss), Effective Portion	$ 4	$ (36)
Interest Expense [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Loss Reclassified from Accumulated OCI into Income, Effective Portion	$ 3	$ 13

Fair Value Measurements (Details) - Derivatives qualifying as hedges [Member] - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Fair Value, Inputs, Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative Liabilities	$ 0	$ 0
Fair Value, Inputs, Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative Liabilities	7	0
Fair Value, Inputs, Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative Liabilities	$ 0	$ 0

Leases (Details 1) $ in Thousands	Mar. 31, 2017 USD ($)
Leases Disclosure [Abstract]
2017	$ 1,610
2018	1,618
2019	1,421
2020	1,098
2021	1,098
Thereafter	1,836
Operating Leases, Total Future Minimum Payments Due	$ 8,681

Leases (Narratives) (Details) - USD ($)	3 Months Ended
Leases (Narratives) (Details) - USD ($)	Mar. 31, 2017	Mar. 31, 2016
Leases Disclosure [Abstract]
Estimated Rental Expenses Current Year	$ 1,700,000
Operating Leases, Rent Expense, Net	$ 400,000	$ 500,000

Income Tax (Narratives) (Details)	3 Months Ended
Income Tax (Narratives) (Details)	Mar. 31, 2017	Mar. 31, 2016
Income Tax [Abstract]
Effective Income Tax Rate	(2.20%)	(43.60%)

Income Tax (Details 1) - USD ($) $ in Thousands	3 Months Ended
Income Tax (Details 1) - USD ($) $ in Thousands	Mar. 31, 2017	Mar. 31, 2016
Income Tax Expense (benefit) Attributable To Income From Continuing Operations [Abstract]
Income Tax Expense, Total	$ 23	$ 193
Effective Tax Rate Reconciliation [Abstract]
Income Tax Expense, Total	23	193
Operating Income (Loss) [Abstract]
Loss before income taxes	$ (1,043)	$ (443)

Employee Benefit Plans (Narratives) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Employee Benefit Plans Disclosure [Abstract]
Expected employer contribution in current remaining fiscal year	$ 0.5
Defined Benefit Plan Payments In Current Fiscal Year	0.2	$ 0.2
Defined Benefit Plans Liabilities Noncurrent	$ 3.2		$ 3.0

Employee Benefit Plans (Details 1) - USD ($) $ in Thousands	3 Months Ended
Employee Benefit Plans (Details 1) - USD ($) $ in Thousands	Mar. 31, 2017	Mar. 31, 2016
Employee Benefit Plans Disclosure [Abstract]
Interest Cost	$ 125	$ 168
Expected Return on Plan Assets	(159)	(181)
Net Amortization Loss	87	80
Net Periodic Benefit Cost, Total	53	67
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
Interest Cost	125	168
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Defined Benefit Plan Payments In Current Fiscal Year	$ 200	$ 200

Capital Stock (Narratives) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016	Apr. 03, 2015
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Employee Stock Purchase Plan Shares Authorized	750,000
Stock issued during the year, Shares, Employee Stock Purchase Plans	725,239
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized				17,508,929
Increase In Number Of Shares Authorized For Issuance Under Stock Option And Incentive Plan				2,500,000
Equity Instruments Other than Options, Grants in Period	445,690
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	5,413,630	5,461,017
Percentage Of Outstanding Common Stock	20.00%
Weighted Average Estimated Black Scholes Value Of Option Grants	$ 1.27	$ 1.11
Preferred Stock - Shares Authorized	5,000,000		5,000,000
Cumulative effect adjustment to retained earnings	$ 0.1
Market Condition Restricted Stock Unit [Member]
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Equity Instruments Other than Options, Grants in Period	0

Capital Stock (Details 1) - $ / shares	3 Months Ended
Capital Stock (Details 1) - $ / shares	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016	Apr. 03, 2015
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Opening Balance Stock Options Outstanding	4,096,818
Begining Balance Weighted Average Exercise Price	$ 3.94
Increase In Number Of Shares Authorized For Issuance Under Stock Option And Incentive Plan				2,500,000
Options, Grants in Period, Gross	30,000
Stock option exercises during the year, Shares	5,709
Options, Forfeitures and Expirations in Period	152,212
Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price	$ 3.68
Closing Balance Stock Options Outstanding	3,968,897
Closing Balance Weighted Average Exercise Price	$ 3.94
Begining Balance Restricted Stock Units Outstanding	1,072,653
Equity Instruments Other than Options, Grants in Period	445,690
Equity Instruments Other than Options, Vested in Period	251,570
Closing Balance Restricted Stock Units Outstanding	1,262,583
Begining Balance Grant Date Fair Value Of Restricted Stock Units	$ 3.15
Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	2.83
Closing Balance Grant Date Fair Value Of Restricted Stock Units	3.01
Weighted Average Fair Value of Vested Restricted Stock	$ 3.28
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Fair Value Assumptions, Expected Volatility Rate	41.07%	40.26%
Fair Value Assumptions, Risk Free Interest Rate	1.89%	1.48%
Fair Value Assumptions, Expected Term	5 years 2 months 12 days	5 years 4 months 9 days
Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%
Options, Exercises in Period, Weighted Average Exercise Price	$ 2.56
Options, Grants in Period, Weighted Average Exercise Price	3.25
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Grant Date Fair Value	$ 3.05
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period	4,190
Preferred Stock - Shares Authorized	5,000,000		5,000,000
Market Condition Restricted Stock Unit [Member]
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Begining Balance Restricted Stock Units Outstanding	182,150
Equity Instruments Other than Options, Grants in Period	0
Equity Instruments Other than Options, Vested in Period	0
Closing Balance Restricted Stock Units Outstanding	182,150
Begining Balance Grant Date Fair Value Of Restricted Stock Units	$ 4.81
Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	0
Closing Balance Grant Date Fair Value Of Restricted Stock Units	4.81
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Grant Date Fair Value	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period	0

Capital Stock (Details 2) - USD ($) $ in Thousands	3 Months Ended
Capital Stock (Details 2) - USD ($) $ in Thousands	Mar. 31, 2017	Mar. 31, 2016
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	$ 863	$ 754
Weighted Average Number Diluted Shares Outstanding Adjustment [Abstract]
Basic	34,579,473	34,013,352
Weighted Average Number Diluted Shares Outstanding Adjustment	0	0
Diluted	34,579,473	34,013,352
Cost of Sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	$ 13	$ 11
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	29	20
Selling and Marketing Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	133	101
General and Administrative Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	$ 688	$ 622

Capital Stock (Details 3) - shares	Mar. 31, 2017	Dec. 31, 2016
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	3,968,897	4,096,818

Related Party Transactions (Narratives) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Business Acquisition [Line Items]
Operating Leases, Rent Expense, Net	$ 400	$ 500
Multi Channel Systems MCS GmbH [Member]
Business Acquisition [Line Items]
Operating Leases, Rent Expense, Net	58	58
Triangle BioSystems, Inc. [Member]
Business Acquisition [Line Items]
Operating Leases, Rent Expense, Net	$ 11	$ 11

Warranties (Details 1) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
Warranties (Details 1) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Product Warranty Disclosure [Abstract]
Warranty, Beginning Balance	$ 193	$ 147
Warranty payments	3	97
Warranty additions	16	143
Warranty, Ending Balance	$ 206	$ 193

Segment and Related Information (Narratives) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Segment and Related Information Disclosure [Abstract]
Revenues	$ 24,156	$ 26,963

Segment and Related Information (Details 1) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Segment Reporting Information [Line Items]
Revenues	$ 24,156	$ 26,963